Membre Annuaire

Professeurs invités

BONELLA Sara
Physics department, University Rome 1 "La Sapienza"
MIRKIN Michael
Queens College - Department of chemistry and Biochemistry - New York - USA
HALLE Bertil
Université de Lund - Suède
Liste
Accueil Publications

Publications

Found 16 results

Filtres: Auteur est Bardet, V.  [Réinitialiser tous les filtres]
2010
Chapuis, N, Tamburini J, Green AS, Willems L, Bardet V, Park S, Lacombe C, Mayeux P, Bouscary D.  2010.  Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies. Leukemia. 24(10):1686-1699. Abstract
Chapuis, N, Tamburini J, Green AS, Vignon C, Bardet V, Neyret A, Pannetier M, Willems L, Park S, Macone A et al..  2010.  Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia. Clinical Cancer Research. 16(22):5424-5435. Abstract
Chapuis, N, Park S, Leotoing L, Tamburini J, Verdier F, Bardet V, Green AS, Willems L, Agou F, Ifrah N et al..  2010.  I kappa B kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia. Blood. 116(20):4240-4250. Abstract
Green, AS, Chapuis N, Maciel TT, Willems L, Lambert M, Arnoult C, Boyer O, Bardet V, Park S, Foretz M et al..  2010.  The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood. 116(20):4262-4273. Abstract
Park, S, Chapuis N, Tamburini J, Bardet V, Cornillet-Lefebvre P, Willems L, Green A, Mayeux P, Lacombe C, Bouscary D.  2010.  Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica-the Hematology Journal. 95(5):819-828. Abstract
Chapuis, N, Tamburini J, Cornillet-Lefebvre P, Gillot L, Bardet V, Willems L, Park S, Green AS, Ifrah N, Dreyfus F et al..  2010.  Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica-the Hematology Journal. 95(3):415-423. Abstract
Bardet, V, Green A, Vergez F, Tamburini J, Gallay N, Gaillard B, Pannetier M, Neyret A, Chapuis N, Ifrah N et al..  2010.  A HIGH AMOUNT OF CD34(+) CD38LOW/NEG CD123(+) CELLS HAS AN ADVERSE IMPACT ON DISEASE FREE AND OVERALL SURVIVAL IN AML PATIENTS TREATED BY INTENSIVE CHEMOTHERAPY. Haematologica-the Hematology Journal. 95:0042.
Chapuis, N, Park S, Leotoing L, Tamburini J, Verdier F, Bardet V, Green A, Willems L, Agou F, Ifrah N et al..  2010.  I-B KINASE OVERCOMES PI3K/AKT AND ERK/MAPK TO CONTROL FOXO3A ACTIVITY IN ACUTE MYELOID LEUKEMIA. Haematologica-the Hematology Journal. 95:0058.
Willems, L, Chapuis N, Green A, Bardet V, Jacque N, Park S, Ifrah N, Dreyfus F, Guichard S, Mayeux P et al..  2010.  Targeted inhibition of mtor by azd8055 blocks protein translation and has anti-leukemic activity in acute myeloid leukemia. Haematologica-the Hematology Journal. 95:0044.
2009
Chapuis, N, Park S, Leotoing L, Tamburini J, Verdier F, Bardet V, Green AS, Agou F, Bismuth G, Baud V et al..  2009.  I kappa B Kinase Overcomes PI3K to Control FoxO3a Subcellular Localization in Acute Myeloid Leukemia. Blood. 114(22):197-197.
Frisan, E, Pawlikowska P, Pierre-Eugene C, Bardet V, Gibault L, Viallon V, Kosmider O, Verdier F, Park S, Kuhnowsky F et al..  2009.  P-ERK1/2 Is a Predictive Factor of Response to ESA Treatment in Myelodysplastic Syndromes. Blood. 114(22):124-124.
Chapuis, N, Tamburini J, Macone A, Green AS, Bardet V, Willems L, Park S, Ifrah N, Dreyfus F, Maira SM et al..  2009.  The PI3K/mTOR Inhibitor NVP-BEZ235 Is a Promising Pre-Clinical Candidate for Therapeutic Intervention in Acute Myeloid Leukemia. Blood. 114(22):423-424.
Pawlikowska, P, Kosmider O, Park S, Bardet V, Kuhnowsky F, Pierre-Eugene C, Picard F, Viallon V, Viguie F, Mayeux P et al..  2009.  Biological factors of response to erythropoiesis-stimulating agents in low/int-1 grade MDS. Leukemia Research. 33:S51-S52.
Green, AS, Willems L, Chapuis N, Bardet V, Park S, Foretz M, Viollet B, Dedhin N, Azar N, Ifrah N et al..  2009.  THE AMP-KINASE AGONIST METFORMIN HAS TUMOR SUPPRESSOR ACTIVITY IN ACUTE MYELOID LEUKEMIA. Haematologica-the Hematology Journal. 94:0277.
Tamburini, J, Green AS, Chapuis N, Bardet V, Lacombe C, Mayeux P, Bouscary D.  2009.  Targeting translation in acute myeloid leukemia A new paradigm for therapy? Cell Cycle. 8(23):3893-3899. Abstract
Tamburini, J, Green AS, Bardet V, Chapuis N, Park S, Willems L, Uzunov M, Ifrah N, Dreyfus F, Lacombe C et al..  2009.  Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood. 114(8):1618-1627. Abstract